
    
      A single blinded prospective randomized controlled trial conducted in family medicine
      outpatients clinics in Jordan. The study enrolled 199 patients met the National Cholesterol
      Education Program Adult Treatment Panel III (NCEP/ATPIII) criteria for the diagnosis of MS
      upon the time of enrollment. Patients were randomized into: 110 participants into the
      intervention arm (pharmacist-physician collaborative approach) and 89 into the control arm
      (physician only team). Only patients in the intervention arm were provided pharmacist
      recommendations and pharmaceutical care counseling.
    
  